InvestorsHub Logo
Followers 51
Posts 9097
Boards Moderated 1
Alias Born 10/25/2007

Re: BottomBounce post# 12783

Wednesday, 06/21/2023 7:35:42 AM

Wednesday, June 21, 2023 7:35:42 AM

Post# of 13469
Research and development expenses for the first quarter of 2023 increased by 104% to $1.1 billion, in comparison to the same quarter of 2022. The growth in spending was mainly due to an increase in clinical trial-related expenses, largely driven by increased clinical development activities, particularly with respect to the Company's RSV, seasonal flu and CMV programs. The growth was also driven by an increase in personnel-related costs, due to increased headcount to support research and development efforts, and the Company's recently announced collaboration agreements with Life Edit and Generation Bio....

this is called business...for the future!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News